News for '-imatinib-mesylate'

Natco opposes Novartis patent claim

Natco Pharma has opposed an application made by Novartis India to the controller of patents, for grant of a patent for an anti-cancer drug 'Imatinib Mesylate'.

8 anti-cancer drugs to be categorised as essential

Eight commonly prescribed anti-cancer drugs will soon enter India's National List of Essential Medicines (NLEM).

Novartis gets patent for cancer drug

Novartis markets Nilotinib globally as Tasigna, which is used as the second-line therapy for Gleevec-resistant patients in the case of chronic myelogenous leukemia.

HC rejects Novartis' plea on patent

The Madras High Court on Monday dismissed a petition filed by Swiss pharmaceutical major Novartis AG, challenging the constitutional validity of the section 3 (d) of the Patents (Amendment) Act 2005.

Novartis denied patent for cancer drug

Sun Pharma sues Novartis in US court

In a development that could hasten the entry of the generic version of Gleevec into the US market, Indian drug major Sun Pharma has sued Novartis Pharmaceuticals Corp in the District Court of New Jersey, demanding rights to launch a generic version of the cancer drug before the Novartis patent expires.

Dr Reddy's A-team moves on putting house in order

After spending considerable time and energy in remediation efforts in the wake of the US Food and Drug Administration's warning letter on compliance issues, the company's leadership has finally set out to bring the house in order.

Markets settle near 3-week low; ITC tanks nearly 7%

According to market experts, GST Bill, movement of the rupee and uncertain global cues amid expected rate cut by the US Fed will dictate the movement of the markets.